دورية أكاديمية
أعرض في EDS

A human immune system (HIS) mouse model that dissociates roles for mouse and human FcR + cells during antibody-mediated immune responses.

التفاصيل البيبلوغرافية
العنوان: A human immune system (HIS) mouse model that dissociates roles for mouse and human FcR + cells during antibody-mediated immune responses.
المؤلفون: Thaller AL; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Jönsson F; Institut Pasteur, Antibodies in Therapy and Pathology Unit, Université Paris Cité, Inserm U1222, Paris, France., Fiquet O; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Marie S; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Doisne JM; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Girelli-Zubani G; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Eri T; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Fernandes P; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Tatirovsky E; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Langa-Vives F; Institut Pasteur, Mouse Genetics Engineering Platform, Université Paris Cité, Paris, France., Bruhns P; Institut Pasteur, Antibodies in Therapy and Pathology Unit, Université Paris Cité, Inserm U1222, Paris, France., Strick-Marchand H; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France., Di Santo JP; Institut Pasteur, Innate Immunity Unit, Université Paris Cité, Inserm U1223, Paris, France.
المصدر: European journal of immunology [Eur J Immunol] 2023 Dec; Vol. 53 (12), pp. e2350454. Date of Electronic Publication: 2023 Aug 31.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 1273201 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-4141 (Electronic) Linking ISSN: 00142980 NLM ISO Abbreviation: Eur J Immunol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005->: Weinheim : Wiley-VCH
Original Publication: Weinheim, Verlag Chemie GmbH.
مواضيع طبية MeSH: Receptors, Fc* , Receptors, IgG*/genetics, Humans ; Mice ; Animals ; Immunoglobulin G ; Antibody-Dependent Cell Cytotoxicity ; Macrophages ; Complement System Proteins ; Adaptive Immunity
مستخلص: Human immune system (HIS) mice provide a model to study human immune responses in vivo. Currently available HIS mouse models may harbor mouse Fc Receptor (FcR)-expressing cells that exert potent effector functions following administration of human Ig. Previous studies showed that the ablation of the murine FcR gamma chain (FcR-γ) results in loss of antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis in vivo. We created a new FcR-γ-deficient HIS mouse model to compare host (mouse) versus graft (human) effects underlying antibody-mediated immune responses in vivo. FcR-γ-deficient HIS recipients lack expression and function of mouse activating FcRs and can be stably and robustly reconstituted with human immune cells. By screening blood B-cell depletion by rituximab Ig variants, we found that human FcγRs-mediated IgG1 effects, whereas mouse activating FcγRs were dominant in IgG4 effects. Complement played a role as an IgG1 variant (IgG1 K322A) lacking complement binding activity was largely ineffective. Finally, we provide evidence that FcγRIIIA on human NK cells could mediate complement-independent B-cell depletion by IgG1 K322A. We anticipate that our FcR-γ-deficient HIS model will help clarify mechanisms of action of exogenous administered human antibodies in vivo.
(© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.)
References: van Zyl, D. G., Tsai, M.-H., Shumilov, A., Schneidt, V., Poirey, R., Schlehe, B., Fluhr, H. et al., Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog. 2018. 14: e1007464.
Masse-Ranson, G., Dusséaux, M., Fiquet, O., Darche, S., Boussand, M., Li, Y., Lopez-Lastra, S. et al., Accelerated thymopoiesis and improved T-cell responses in HLA-A2/-DR2 transgenic BRGS-based human immune system mice. Eur. J. Immunol. 2019. 49: 954-965.
Capasso, A., Lang, J., Pitts, T. M., Jordan, K. R., Lieu, C. H., Davis, S. L., Diamond, J. R. et al., Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J. Immunother. Cancer 2019. 7: 37.
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M. et al., Human LYMPHOID and myeloid cell development in NOD/LtSz-scid IL2R γ null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 2005. 174: 6477-6489.
Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y. et al., NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002. 100: 3175-3182.
Legrand, N., Huntington, N. D., Nagasawa, M., Bakker, A. Q., Schotte, R., Strick-Marchand, H., De Geus, S. J. et al., Functional CD47/signal regulatory protein alpha (SIRPα) interaction is required for optimal human T- and natural killer-(NK) cell homeostasis in vivo. Proc. Natl. Acad. Sci. USA 2011. 108: 13224-13229.
Mullard, A., FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 2021. 20: 491-495.
Reinherz, E. L., Hussey, R. E. and Schlossman, S. F., A monoclonal antibody blocking human T cell function. Eur. J. Immunol. 1980. 10: 758-762.
Kaye, J., Porcelli, S., Tite, J., Jones, B. and Janeway, C. A., Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J. Exp. Med. 1983. 158: 836-856.
Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., Newman, R. A. et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994. 15: 435-445.
Könitzer, J. D., Sieron, A., Wacker, A. and Enenkel, B., Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PLoS One 2015. 10: e0145633.
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M. et al., Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003. 171: 1581-1587.
Walbaum, S., Ambrosy, B., Schütz, P., Bachg, A. C., Horsthemke, M., Leusen, J. H. W., Mócsai, A. et al., Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. J. Biol. Chem. 2021. 296: 100256.
Bruhns, P. and Jönsson, F., Mouse and human FcR effector functions. Immunol. Rev. 2015. 268: 25-51.
Yu, J., Song, Y. and Tian, W., How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J. Hematol. Oncol. 2020. 13: 45.
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S. and Daëron, M., Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009. 113: 3716-3725.
Li, Y., Mention, J-J., Court, N., Masse-Ranson, G., Toubert, A., Spits, H., Legrand, N. et al., A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development. Eur. J. Immunol. 2016. 46: 1291-1299.
Yamauchi, T., Takenaka, K., Urata, S., Shima, T., Kikushige, Y., Tokuyama, T., Iwamoto, C. et al., Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment. Blood 2013. 121: 1316-1325.
Lux, A. and Nimmerjahn, F., Of mice and men: the need for humanized mouse models to study human IgG activity in vivo. J. Clin. Immunol. 2013. 33: S4-S8.
Bournazos, S., DiLillo, D. J. and Ravetch, J. V., Humanized mice to study FcγR function. Curr. Top. Microbiol. Immunol. 2014. 382: 237-248.
Overdijk, M. B., Verploegen, S., Ortiz Buijsse, A., Vink, T., Leusen, J. H. W., Bleeker, W. K. and Parren, P. W. H. I., Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 2012. 189: 3430-3438.
Wang, Yu., Krémer, V., Iannascoli, B., Goff, O. R-Le., Mancardi, D. A., Ramke, L., De Chaisemartin, L. et al., Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species. Eur. J. Immunol. 2022. 52: 753-759.
Lux, A., Seeling, M., Baerenwaldt, A., Lehmann, B., Schwab, I., Repp, R., Meidenbauer, N. et al., A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep. 2014. 7: 236-248.
Katano, I., Ito, R., Kawai, K. and Takahashi, T., Improved detection of in vivo human NK cell-mediated antibody-dependent cellular cytotoxicity using a novel NOG-FcγR-deficient human IL-15 transgenic mouse. Front. Immunol. 2020. 11: 532684.
Takai, T., Li, M., Sylvestre, D., Clynes, R. and Ravetch, J. V., FcR γ chain deletion results in pleiotrophic effector cell defects. Cell 1994. 76: 519-529.
Nimmerjahn, F., Bruhns, P., Horiuchi, K. and Ravetch, J. V., FcγRIV: a novel FcR with distinct igg subclass specificity. Immunity 2005. 23: 41-51.
Beutier, H., Gillis, C. M., Iannascoli, B., Godon, O., England, P., Sibilano, R., Reber, L. L. et al., IgG subclasses determine pathways of anaphylaxis in mice. J. Allergy Clin. Immunol. 2017. 139: 269-280.e7.
Strowig, T., Gurer, C., Ploss, A., Liu, Y.-F., Arrey, F., Sashihara, J., Koo, G. et al., Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 2009. 206: 1423-1434.
Chijioke, O., Müller, A., Feederle, R., Barros, M. H. M., Krieg, C., Emmel, V., Marcenaro, E. et al., Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep. 2013. 5: 1489-1498.
Leatherbarrow, R. J. and Dwek, R. A., Binding of complement subcomponent Clq to mouse IgGl, IgG2a AND IgG2b: A novel Clq binding assay. Mol. Immunol. 1984. 21: 321-327.
Terry, L. A., DiSanto, J. P., Small, T. N. and Flomenberg, N., Differential expression and regulation of the human CD8α and CD8β chains. Tissue Antigens 1990. 35: 82-91.
Peschke, B., Keller, C. W., Weber, P., Quast, I. and Lünemann, J. D., Fc-galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front. Immunol. 2017. 8: 646.
de Taeye, S. W., Bentlage, A. E. H., Mebius, M. M., Meesters, J. I., Lissenberg-Thunnissen, S., Falck, D., Sénard, T. et al., FcγR binding and ADCC activity of human IgG allotypes. Front. Immunol. 2020. 11: 740.
Steplewski, Z., Sun, L. K., Shearman, C. W., Ghrayeb, J., Daddona, P. and Koprowski, H., Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc. Natl. Acad. Sci. USA 1988. 85: 4852-4856.
Tao, M. H., Smith, R. I. and Morrison, S. L., Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 1993. 178: 661-667.
Brüggemann, M., Williams, G. T., Bindon, C. I., Clark, M. R., Walker, M. R., Jefferis, R., Waldmann, H. et al., Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 1987. 166: 1351-1361.
Derebe, M. G., Nanjunda, R. K., Gilliland, G. L., Lacy, E. R. and Chiu, M. L., Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors. Immunol. Lett. 2018. 197: 1-8.
Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T. et al., Affinity of human IgG subclasses to mouse Fc gamma receptors. mAbs 2017. 9: 767-773.
Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. and Parren, P. W., Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 2001. 75: 12161-12168.
Huntington, N. D., Legrand, N., Alves, N. L., Jaron, B., Weijer, K., Plet, A., Corcuff, E. et al., IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 2009. 206: 25-34.
Titus, J. A., Perez, P., Kaubisch, A., Garrido, M. A. and Segal, D. M., Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J. Immunol. 1987. 139: 3153-3158.
Anderson, C. L., Shen, L., Eicher, D. M., Wewers, M. D. and Gill, J. K., Phagocytosis is mediated by three distinct Fcy receptor classes on human leukocytes. J. Exp. Med. 1990. 171: 1333-1345.
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. and Ravetch, J. V., Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 1998. 95: 652-656.
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M. and Tedder, T. F., The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 2004. 199: 1659-1669.
Albanesi, M., Mancardi, D. A., Jönsson, F., Iannascoli, B., Fiette, L., Di Santo, J. P., Lowell, C. A. et al., Neutrophils mediate antibody-induced antitumor effects in mice. Blood 2013. 122: 3160-3164.
Montalvao, F., Garcia, Z., Celli, S., Breart, B., Deguine, J., Van Rooijen, N. and Bousso, P., The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imaging. J. Clin. Invest. 2013. 123: 5098-5103.
Schwab, I., Lux, A. and Nimmerjahn, F., Pathways responsible for human autoantibody and therapeutic intravenous IgG activity in humanized mice. Cell Rep. 2015. 13: 610-620.
Katano, I., Hanazawa, A., Otsuka, I., Yamaguchi, T., Mochizuki, M., Kawai, K., Ito, R. et al., Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody. Sci. Rep. 2021. 11: 21087.
Czajkowsky, D. M., Hu, J., Shao, Z. and Pleass, R. J., Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med. 2012. 4: 1015-1028.
Lopez-Lastra, S., Masse-Ranson, G., Fiquet, O., Darche, S., Serafini, N., Li, Y., Dusséaux, M. et al., A functional DC cross talk promotes human ILC homeostasis in humanized mice. Blood Adv. 2017. 1: 601-614.
Haeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J-B., Schneider-Maunoury, S. et al., Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016. 17: 148.
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A. and Zhang, F., Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 2013. 8: 2281-2308.
Mashiko, D., Fujihara, Y., Satouh, Y., Miyata, H., Isotani, A. and Ikawa, M., Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci. Rep. 2013. 3: 3355.
Cossarizza, A., Chang, H-D., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I. et al., Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur. J. Immunol. 2021. 51: 2708-3145.
Li, Y., Masse-Ranson, G., Garcia, Z., Bruel, T., Kök, A., Strick-Marchand, H., Jouvion, G. et al., A human immune system mouse model with robust lymph node development. Nat. Methods 2018. 15: 623-630.
Silva, J.-P., Vetterlein, O., Jose, J., Peters, S. and Kirby, H., The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J. Biol. Chem. 2015. 290: 5462-5469.
معلومات مُعتمدة: ECTZ91652 Institut National de la Santé et de la Recherche Médicale; Institut Pasteur; 765104 European Union's Horizon 2020 research and innovation program
فهرسة مساهمة: Keywords: ADCC; Antibody-mediated immune responses; Fc receptors; Human immune system (HIS) mice; NK cells
المشرفين على المادة: 0 (Receptors, Fc)
0 (Receptors, IgG)
0 (Immunoglobulin G)
9007-36-7 (Complement System Proteins)
تواريخ الأحداث: Date Created: 20230825 Date Completed: 20231220 Latest Revision: 20231220
رمز التحديث: 20231220
DOI: 10.1002/eji.202350454
PMID: 37621208
قاعدة البيانات: MEDLINE
الوصف
تدمد:1521-4141
DOI:10.1002/eji.202350454